Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings, Inc. (ASBP) is an early-stage biopharmaceutical company developing sublingual delivery technologies for drugs and supplements, focusing on high-dose sublingual aspirin for faster absorption to treat heart attacks and strokes, bypassing gastric issues of oral aspirin. The company completed a reverse recapitalization via merger with PowerUp Acquisition Corp. on February 17, 2025, becoming publicly traded on Nasdaq. Key products include patent-pending formulations for aspirin (applications 63/456,290 and 63/702,381), melatonin, vitamins, ED medication, caffeine supplements (Buzz Bomb, with 2M units manufactured January 2026), and others like anti-nausea and nicotine. Clinical trials completed July 2025 showed faster bioavailability; FDA pre-IND response November 11, 2025 approved next trial for 2026 NDA submission under 505(b)(2). This S-1 registers resale of up to 159,090,906 common shares issuable upon conversion of 13,750 Series A Preferred shares issued February 6, 2026 for $11M gross proceeds (including $943,801 debt conversion), at 80% of 5-day low VWAP (floor $0.264). Company reports $1,941 revenue Q3 2025 from caffeine sales, $19.8M net loss nine months ended September 30, 2025, $11.5M working capital deficit, and Nasdaq compliance issues (regained bid price February 3, 2026). Investment thesis centers on sublingual tech's potential for rapid-acting aspirin FDA approval and pipeline expansion, though pre-revenue with ongoing losses and dilution risks.

Key Takeaways